Pfizer, Amgen Chase Novo, Lilly in GLP-1 Weight Loss
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GLP-1 weight loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound have been on the market for a few years and are wildly popular, establishing a lucrative category.
- Pfizer and Amgen are developing similar GLP-1 drugs to grab a piece of the weight loss market currently led by Novo Nordisk and Eli Lilly.
- Novo Nordisk and Eli Lilly are working on new products of their own to stay dominant in the weight loss marketplace as new competitors close in.
- STAT is framing the GLP-1 competitive landscape as a 'head-spinning news cycle,' with the STATus Report this week focused squarely on the pharma side of the land grab.
- The Readout LOUD podcast team at STAT is weighing in on the GLP-1 market dynamics, signaling STAT is treating this as a story worth sustained coverage rather than a one-off trend piece.
Why it matters: With Wegovy and Zepbound already described as safe, effective, and wildly popular, the entry of Pfizer and Amgen into the GLP-1 space sets up a multi-player race where Novo Nordisk and Eli Lilly are simultaneously defending their lead and developing next-generation products to stay ahead.
